{"id":745458,"date":"2017-11-09T06:45:00","date_gmt":"2017-11-09T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/"},"modified":"2025-11-07T01:26:09","modified_gmt":"2025-11-07T06:26:09","slug":"merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/","title":{"rendered":"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients"},"content":{"rendered":"<p class=\"bwalignc\">       CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause        Mortality Through Week 24 and Week 48 Post-Transplant     <\/p>\n<p>\n      Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that the U.S. Food and Drug Administration<br \/>\n      (FDA) has approved PREVYMIS\u2122 (letermovir) once-daily tablets for oral<br \/>\n      use and injection for intravenous infusion. PREVYMIS is indicated for<br \/>\n      prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease<br \/>\n      in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic<br \/>\n      stem cell transplant (HSCT).\n    <\/p>\n<p>\n      CMV is a common and potentially serious viral infection in allogeneic<br \/>\n      HSCT recipients. CMV-seropositive patients who undergo an HSCT are at<br \/>\n      high risk for CMV reactivation. Any level of CMV infection is associated<br \/>\n      with increased mortality in HSCT patients.\n    <\/p>\n<p>\n      In the pivotal Phase 3 clinical trial supporting approval, significantly<br \/>\n      fewer patients in the PREVYMIS group (38%, n=122\/325) compared to the<br \/>\n      placebo group (61%, n=103\/170) developed clinically significant CMV<br \/>\n      infection, discontinued treatment or had missing data through Week 24<br \/>\n      post-HSCT [treatment difference: -23.5 (95% confidence interval -32.5 to<br \/>\n      -14.6), (p&lt;0.0001)], the primary efficacy endpoint. All-cause mortality<br \/>\n      in patients receiving PREVYMIS was lower compared to placebo, 12% vs.<br \/>\n      17%, respectively, at week 24 post-transplant. In this study, the<br \/>\n      incidence of bone marrow suppression in the PREVYMIS group was<br \/>\n      comparable to the placebo group. The median time to engraftment was 19<br \/>\n      days in the PREVYMIS group and 18 days in the placebo group.\n    <\/p>\n<p>\n      PREVYMIS is contraindicated in patients receiving pimozide or ergot<br \/>\n      alkaloids. Increased pimozide concentrations may lead to QT prolongation<br \/>\n      and torsades de pointes. Increased ergot alkaloids concentrations may<br \/>\n      lead to ergotism. PREVYMIS is contraindicated with pitavastatin and<br \/>\n      simvastatin when co-administered with cyclosporine. Significantly<br \/>\n      increased pitavastatin or simvastatin concentrations may lead to<br \/>\n      myopathy or rhabdomyolysis.\n    <\/p>\n<p>\n      The concomitant use of PREVYMIS (letermovir) and certain drugs may<br \/>\n      result in potentially significant drug interactions, some of which may<br \/>\n      lead to adverse reactions (PREVYMIS or concomitant drugs) or reduced<br \/>\n      therapeutic effect of PREVYMIS or the concomitant drug. Consider the<br \/>\n      potential for drug interactions prior to and during PREVYMIS therapy;<br \/>\n      review concomitant medications during PREVYMIS therapy; and monitor for<br \/>\n      adverse reactions associated with PREVYMIS and concomitant medications.\n    <\/p>\n<p>\n      \u201cOur findings demonstrate that letermovir is a significant and welcomed<br \/>\n      advance in the prevention of clinically significant CMV infection and<br \/>\n      lowers mortality in this highly vulnerable patient population,\u201d said Dr.<br \/>\n      Francisco M. Marty, associate professor of medicine at Harvard Medical<br \/>\n      School and attending physician in transplant and oncology infectious<br \/>\n      diseases at Dana-Farber Cancer Institute and Brigham and Women\u2019s<br \/>\n      Hospital in Boston.\n    <\/p>\n<p>\n      The recommended dosage of PREVYMIS is 480 mg administered once daily,<br \/>\n      initiated as early as Day 0 and up to Day 28 post-transplantation<br \/>\n      (before or after engraftment), and continued through Day 100<br \/>\n      post-transplantation. If PREVYMIS is co-administered with cyclosporine,<br \/>\n      the dosage of oral or intravenous PREVYMIS should be decreased to 240 mg<br \/>\n      once daily. PREVYMIS is available as 240 mg and 480 mg tablets, which<br \/>\n      may be administered with or without food. PREVYMIS is also available as<br \/>\n      240 mg and 480 mg injection for intravenous infusion via a peripheral<br \/>\n      catheter or central venous line at a constant rate over one hour.\n    <\/p>\n<p>\n      \u201cPREVYMIS is the first new medicine for CMV infection approved in the<br \/>\n      U.S. in 15 years,\u201d said Dr. Roy Baynes, senior vice president, head of<br \/>\n      clinical development, and chief medical officer, Merck Research<br \/>\n      Laboratories. \u201cPREVYMIS continues Merck\u2019s longstanding tradition of<br \/>\n      bringing forward important new therapies to address serious infectious<br \/>\n      diseases. We are proud to add this breakthrough medicine to our existing<br \/>\n      offerings for physicians and patients.\u201d\n    <\/p>\n<p>\n      PREVYMIS is expected to be available in December. The list price<br \/>\n      (wholesaler acquisition cost) per day for PREVYMIS tablets is $195.00<br \/>\n      and for PREVYMIS injection is $270.00. Wholesaler acquisition costs do<br \/>\n      not include discounts that may be paid on the product.\n    <\/p>\n<p>\n      The cardiac adverse event rate (regardless of investigator-assessed<br \/>\n      causality) was higher in patients receiving PREVYMIS than placebo (13%<br \/>\n      vs. 6%). The most common cardiac adverse events were tachycardia<br \/>\n      (reported in 4% PREVYMIS patients and 2% placebo patients) and atrial<br \/>\n      fibrillation (reported in 3% PREVYMIS patients and 1% placebo patients).<br \/>\n      These adverse events were reported as mild or moderate in severity. The<br \/>\n      rate of adverse events occurring in at least 10% of PREVYMIS-treated<br \/>\n      HSCT recipients and at a frequency at least 2% greater than placebo were<br \/>\n      nausea (27% vs. 23%), diarrhea (26% vs. 24%), vomiting (19% vs. 14%),<br \/>\n      peripheral edema (14% vs. 9%), cough (14% vs. 10%), headache (14% vs.<br \/>\n      9%), fatigue (13% vs. 11%), and abdominal pain (12% vs. 9%). The most<br \/>\n      frequently reported adverse event that led to study drug discontinuation<br \/>\n      was nausea (occurring in 2% of PREVYMIS patients and 1% of placebo<br \/>\n      patients). Hypersensitivity reaction, with associated moderate dyspnea,<br \/>\n      occurred in one patient following the first infusion of IV PREVYMIS<br \/>\n      after switching from oral PREVYMIS, leading to treatment discontinuation.\n    <\/p>\n<p>\n      <b>Clinical data supporting PREVYMIS (letermovir)<\/b>\n    <\/p>\n<p>\n      To evaluate prophylaxis with PREVYMIS as a preventive strategy for CMV<br \/>\n      infection or disease in transplant recipients at high risk for CMV<br \/>\n      reactivation, the efficacy of PREVYMIS was assessed in a multicenter,<br \/>\n      double-blind, placebo-controlled Phase 3 trial in adult CMV-positive<br \/>\n      recipients [R+] of an allogeneic HSCT. Patients were randomized (2:1) to<br \/>\n      receive either PREVYMIS at a dose of 480 mg once daily adjusted to 240<br \/>\n      mg when co-administered with cyclosporine, or placebo. Study drug was<br \/>\n      initiated after HSCT (at any time from Day 0-28 post-transplant) and<br \/>\n      continued through Week 14 post-transplant. Patients were monitored<br \/>\n      through Week 24 post-transplant for the primary efficacy endpoint, with<br \/>\n      continued follow-up through Week 48 post-transplant. The primary<br \/>\n      efficacy endpoint was the incidence of clinically significant CMV<br \/>\n      infection through Week 24 post-transplant, defined as the occurrence of<br \/>\n      either CMV end-organ disease, or initiation of anti-CMV pre-emptive<br \/>\n      therapy based on documented CMV viremia and the clinical condition of<br \/>\n      the patient. The Non-Completer equals Failure approach was used, where<br \/>\n      patients who discontinued from the trial prior to Week 24<br \/>\n      post-transplant or had a missing outcome at Week 24 post-transplant were<br \/>\n      counted as failures.\n    <\/p>\n<p>\n      Among the 565 treated patients, 34% were engrafted at baseline and 30%<br \/>\n      had one or more factors associated with additional risk for CMV<br \/>\n      reactivation. The most common primary reasons for transplant were acute<br \/>\n      myeloid leukemia (38%), myelodysplastic syndrome (16%), and lymphoma<br \/>\n      (12%).\n    <\/p>\n<p>\n      Fewer patients in the PREVYMIS group had clinically significant CMV<br \/>\n      infection by Week 24 post-HSCT compared to the placebo group, 18% vs.<br \/>\n      42%, respectively. Through the Week 14 post-HSCT treatment period, 8% of<br \/>\n      patients in the PREVYMIS group and 39% of patients in the placebo group<br \/>\n      experienced clinically significant CMV infection. Clinically significant<br \/>\n      CMV infection was defined as CMV end-organ disease or initiation of<br \/>\n      pre-emptive therapy based on documented CMV viremia and the clinical<br \/>\n      condition of the patient.\n    <\/p>\n<p>\n      Efficacy results were consistent across high- and low-risk strata for<br \/>\n      CMV reactivation.\n    <\/p>\n<p>\n      PREVYMIS demonstrated significant benefit compared to placebo in time to<br \/>\n      clinically significant CMV infection through Week 24 post-HSCT (18.9%<br \/>\n      vs. 44.3% cumulative rate; stratified log-rank test, two-sided p-value<br \/>\n      &lt;0.0001). Post-hoc analysis demonstrated that among PREVYMIS-treated<br \/>\n      patients, inclusion in the high-risk stratum for CMV reactivation at<br \/>\n      baseline, occurrence of graft-versus-host disease (GVHD), and steroid<br \/>\n      use at any time after randomization may be associated with the<br \/>\n      development of clinically significant CMV infection between Week 14 and<br \/>\n      Week 24 post-transplant.\n    <\/p>\n<p>\n      The Kaplan-Meier event rate for all-cause mortality in the PREVYMIS vs.<br \/>\n      placebo groups was 12% vs. 17% at Week 24 post-transplant, and 24% vs.<br \/>\n      28% at Week 48 post-transplant.\n    <\/p>\n<p>\n      <b>Additional Selected Safety Information about PREVYMIS (letermovir)<\/b>\n    <\/p>\n<p>\n      Co-administration of PREVYMIS with drugs that are inhibitors of organic<br \/>\n      anion-transporting polypeptide 1B1\/3 (OATP1B1\/3) transporters may result<br \/>\n      in increases in letermovir plasma concentrations.\n    <\/p>\n<p>\n      Co-administration of PREVYMIS with midazolam results in increased<br \/>\n      midazolam plasma concentration. Co-administration of PREVYMIS with drugs<br \/>\n      that are CYP3A substrates may result in clinically relevant increases in<br \/>\n      the plasma concentrations of co-administered CYP3A substrates.\n    <\/p>\n<p>\n      Co-administration of PREVYMIS with drugs that are substrates of<br \/>\n      OATP1B1\/3 transporters may result in a clinically relevant increase in<br \/>\n      plasma concentrations of co-administered OATP1B1\/3 substrates.\n    <\/p>\n<p>\n      The magnitude of CYP3A- and OATP1B1\/3-mediated drug interactions on<br \/>\n      co-administered drugs may be different when PREVYMIS is co-administered<br \/>\n      with cyclosporine. See the prescribing information for cyclosporine for<br \/>\n      information on drug interactions with cyclosporine.\n    <\/p>\n<p>\n      If dose adjustments of concomitant medications are made due to treatment<br \/>\n      with PREVYMIS, doses should be readjusted after PREVYMIS treatment is<br \/>\n      completed.\n    <\/p>\n<p>\n      Established or potentially clinically significant drug interactions may<br \/>\n      occur with co-administration of PREVYMIS and drug\/drug classes (without<br \/>\n      cyclosporine, unless otherwise indicated), including, but not limited<br \/>\n      to, the following:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Anti-arrhythmic agents<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Amiodarone: increases amiodarone concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Anticoagulants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Warfarin: decreases warfarin concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Anticonvulsants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Phenytoin: decreases phenytoin concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antidiabetic agents<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Glyburide: increases glyburide concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Repaglinide: increases repaglinide concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Rosiglitazone: increases rosiglitazone concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antifungals<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Voriconazole: decreases voriconazole concentration\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Antimycobacterial<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Rifampin: decreases letermovir concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antipsychotics<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Pimozide: increases pimozide concentration; co-administration is<br \/>\n            contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Ergot alkaloids<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Ergotamine: increases ergotamine concentration; co-administration<br \/>\n            is contraindicated\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Dihydroergotamine: increases dihydroergotamine concentration;<br \/>co-administration<br \/>\n            is contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        HMG-CoA reductase inhibitors<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Pitavastatin, Simvastatin: increases HMG-CoA reductase inhibitors<br \/>\n            concentration; co-administration is contraindicated when PREVYMIS<br \/>\n            is co-administered with cyclosporine\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Atorvastatin: increases atorvastatin concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin: increases<br \/>\n            HMG-CoA reductase inhibitors concentration\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Immunosuppressants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Cyclosporine: increases both cyclosporine and letermovir<br \/>\n            concentrations\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Sirolimus: increases sirolimus concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Tacrolimus: increases tacrolimus concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Proton pump inhibitors<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Omeprazole: decreases omeprazole concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Pantoprazole: decreases pantoprazole concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        CYP3A substrate examples<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Alfentanil, fentanyl, midazolam and quinidine: may increase CYP3A<br \/>\n            substrate concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Pimozide and ergot alkaloids are contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      The safety and efficacy of PREVYMIS (letermovir) in patients below 18<br \/>\n      years of age have not been established.\n    <\/p>\n<p>\n      For patients with CLcr greater than 10 mL\/min (by Cockcroft-Gault<br \/>\n      equation), no dosage adjustment of PREVYMIS is required based on renal<br \/>\n      impairment. The safety of PREVYMIS in patients with end-stage renal<br \/>\n      disease (CLcr less than 10 mL\/min), including patients on dialysis, is<br \/>\n      unknown.\n    <\/p>\n<p>\n      No dosage adjustment of PREVYMIS is required based on mild (Child-Pugh<br \/>\n      Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVYMIS<br \/>\n      is not recommended for patients with severe (Child-Pugh Class C) hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      <b>About PREVYMIS (letermovir)<\/b>\n    <\/p>\n<p>\n      PREVYMIS is a member of a new class of non-nucleoside CMV inhibitors<br \/>\n      (3,4 dihydro-quinazolines) and inhibits viral replication by<br \/>\n      specifically targeting the viral terminase complex. Cross resistance is<br \/>\n      not likely with drugs outside of this class. PREVYMIS is fully active<br \/>\n      against viral populations with substitutions conferring resistance to<br \/>\n      CMV DNA polymerase inhibitors. These DNA polymerase inhibitors are fully<br \/>\n      active against viral populations with substitutions conferring<br \/>\n      resistance to PREVYMIS. PREVYMIS has no activity against other viruses.<br \/>\n      Letermovir has been granted orphan designation for the prevention of CMV<br \/>\n      disease in at-risk populations in the U.S., EU and Japan, and is under<br \/>\n      accelerated review in the EU and Japan.\n    <\/p>\n<p>\n      Under an agreement signed in 2012, Merck (through a subsidiary)<br \/>\n      purchased worldwide rights to develop and commercialize letermovir from<br \/>\n      AiCuris GmbH &amp; Co KG (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aicuris.com&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=www.aicuris.com&amp;index=1&amp;md5=00fbd8c24317422db1db3f7f1a14c82f\" rel=\"nofollow\">www.aicuris.com<\/a>).\n    <\/p>\n<p>\n      <b>About CMV and Treatment<\/b>\n    <\/p>\n<p>\n      CMV is a common virus that infects people of all ages. Many adults in<br \/>\n      the United States are CMV seropositive, meaning they have CMV antibodies<br \/>\n      in their blood, indicating a previous exposure to or primary infection<br \/>\n      with CMV. People with normal immune systems rarely develop CMV symptoms<br \/>\n      after initial infection, with the virus typically remaining inactive or<br \/>\n      latent in the body for life. A weakened immune system may give the virus<br \/>\n      a chance to reactivate, potentially leading to symptomatic disease or a<br \/>\n      secondary infection due to other pathogens. CMV disease can lead to<br \/>\n      end-organ damage, including gastrointestinal tract disease, pneumonia or<br \/>\n      retinitis. Transplant recipients who develop CMV infection<br \/>\n      post-transplant are at increased risk for transplant failure and death.<br \/>\n      CMV prophylaxis with certain existing antivirals has been associated<br \/>\n      with drug-specific effects, including myelosuppression and renal<br \/>\n      toxicity, in HSCT recipients.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=689c675a331289aa27f4bd8a84bf73f6\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=ea031ff7fc0993eaad7c04d5f42c3ef3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=1db72792c09a6c6763cec36919898b09\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=8acfb2522e8d9fc5723895845ca6ac8d\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=937359be75b4e0da84226e5169da500e\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=2ba0896a75d93b697769833665e0cc6c\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=71bba6b816047985dc2c4c4e6f0e3e0c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for PREVYMIS (letermovir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_pi.pdf&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_pi.pdf&amp;index=9&amp;md5=e22e973840d10fcd6716ed2944efc4c9\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Patient Information for PREVYMIS at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_ppi.pdf&amp;esheet=51713398&amp;newsitemid=20171109005397&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_ppi.pdf&amp;index=10&amp;md5=09d2def1e252372a006ffd4dddf8ed1a\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_ppi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20171109005397r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>Robert Consalvo,        908-740-6518<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause Mortality Through Week 24 and Week 48 Post-Transplant Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS\u2122 (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients. In the pivotal Phase 3 clinical trial supporting approval, significantly fewer patients in the PREVYMIS group (38%, n=122\/325) compared to the placebo group (61%,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745458","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com\" \/>\n<meta property=\"og:description\" content=\"CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause Mortality Through Week 24 and Week 48 Post-Transplant Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS\u2122 (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients. In the pivotal Phase 3 clinical trial supporting approval, significantly fewer patients in the PREVYMIS group (38%, n=122\/325) compared to the placebo group (61%,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\\\/\",\"name\":\"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-11-09T06:45:00+00:00\",\"dateModified\":\"2025-11-07T06:26:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com","og_description":"CMV Prophylaxis with PREVYMIS Associated with Lower All-Cause Mortality Through Week 24 and Week 48 Post-Transplant Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS\u2122 (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). CMV is a common and potentially serious viral infection in allogeneic HSCT recipients. CMV-seropositive patients who undergo an HSCT are at high risk for CMV reactivation. Any level of CMV infection is associated with increased mortality in HSCT patients. In the pivotal Phase 3 clinical trial supporting approval, significantly fewer patients in the PREVYMIS group (38%, n=122\/325) compared to the placebo group (61%,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:09+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/","name":"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-11-09T06:45:00+00:00","dateModified":"2025-11-07T06:26:09+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-of-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-infection-and-disease-in-adult-allogeneic-stem-cell-transplant-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives FDA Approval of PREVYMIS\u2122 (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"6a775b5a-d809-4523-8bc6-b236b819ac7c","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Receives-FDA-Approval-of-PREVYMIS-letermovir-for-Prevention-of-Cytomegalovirus-CMV-Infection-and-Disease-in-Adult-Allogeneic-St-PWEJ6.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745458\/revisions"}],"predecessor-version":[{"id":3674830,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745458\/revisions\/3674830"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745458"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}